Spots Global Cancer Trial Database for Treatment of Oral Warts in HIV+ Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Oral Warts in HIV+ Patients
Official Title: Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial
Study ID: NCT00454181
Study Description
Brief Summary: This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults. The hypothesis of this study is that interferon-alpha will be safe and that a higher percentage of subjects given interferon-alpha will experience a complete or nearly complete remission of their oral warts compared to subjects given placebo.
Detailed Description: Human papilloma virus (HPV) can cause warts to form in the mouth of infected patients, particularly those with reduced immunity such as people infected with HIV. This is a randomized, double-blind, placebo-controlled trial to determine whether interferon-alpha, delivered in low doses via orally dissolving lozenges, can reduce or eliminate these warts in HIV+ subjects who are receiving combination anti-retroviral therapy (HAART). All potential subjects will have their warts examined and measured at a screening visit. A small amount of one wart (i.e. a biopsy) will be removed for microscopic evaluation to confirm HPV infection and a small amount of blood will be collected for testing. Subjects that qualify for entry will return for a baseline visit at which they will be randomized to active or placebo treatment for 24 weeks. Three out of four subjects will receive active treatment in this study. Subjects must return to the clinic every 6 weeks during treatment to have their warts re-examined. At these follow-up visits, subjects will be asked to complete a brief questionnaire regarding any perceived changes in their warts and their overall mouth condition. A small amount of blood will be taken at the final study visit at week 24 to assess the safety of the interferon lozenges.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, School of Dentistry, San Francisco, California, United States
Nova Southeastern University College of Dental Medicine, Fort Lauderdale, Florida, United States
Medical College of Georgia School of Dentistry, Augusta, Georgia, United States
University of Illinois at Chicago, College of Dentistry, Chicago, Illinois, United States
University of Kentucky College of Dentistry, Lexington, Kentucky, United States
University of Maryland Baltimore Dental School, Baltimore, Maryland, United States
Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts, United States
UMDNJ - New Jersey Dental School, Newark, New Jersey, United States
New York University College of Dentistry, New York, New York, United States
University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania, United States
Baylor College of Dentistry, Dallas, Texas, United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Contact Details
Name: Deborah Greenspan, BDS, DSc
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
